Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions)

J Cyst Fibros. 2010 May;9(3):237-8. doi: 10.1016/j.jcf.2010.03.005. Epub 2010 Apr 7.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adult
  • Anti-Bacterial Agents / administration & dosage
  • Cystic Fibrosis / microbiology*
  • Humans
  • Microbial Sensitivity Tests / methods
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / isolation & purification
  • Tobramycin / administration & dosage
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Tobramycin